Insider sale details
Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (NASDAQ: VERA), sold 22,951 shares of the company's Class A common stock on April 14, 2026, for aggregate proceeds of $1,011,050. The dispositions were completed in several tranches at prices ranging from $43.6649 to $45.5114 per share.
Breakdown of the transactions shows 14,130 shares sold at a weighted average price of $43.6649, 7,921 shares sold at a weighted average price of $44.5784, and 900 shares sold at a weighted average price of $45.5114.
Post-sale holdings
After these transactions, Fordyce directly holds 235,244 shares of Vera Therapeutics. In addition to his direct holdings, he has indirect stakes of 122,949 shares held through a grantor retained annuity trust (GRAT) and 99,081 shares held by a Trust.
Trading plan and context
The sales were carried out under a pre-arranged 10b5-1 trading plan that Fordyce adopted on January 9, 2026. The use of such a plan indicates the transactions followed a predetermined schedule or formula established earlier in the year.
Market performance and valuation
VERA shares have gained ground recently, rising 10% over the past week and 105% over the past 12 months. An InvestingPro analysis cited in company information indicates the stock currently trades below its Fair Value, implying potential upside relative to that assessment. The company is assigned a market valuation of $3.1 billion and has its next earnings report scheduled for May 7.
Analyst coverage and competitive signals
Vera has seen several analyst moves and commentary in close succession. Wolfe Research upgraded Vera to an Outperform rating and set a price target of $88.00, citing the resolution of uncertainties tied to a Vertex catalyst. BofA Securities maintained its Buy rating with a $66.00 price target and referenced interim Phase 3 trial data from a key competitor. JPMorgan reiterated an Overweight rating with a $96.00 price target, emphasizing the strategic positioning of Vera's lead candidate, atacicept, in the IgA nephropathy treatment space.
Corporate appointments as commercial preparations advance
In addition to analyst attention, Vera announced leadership changes aimed at advancing commercialization readiness. Christopher Hite has been appointed to the company’s board of directors; his background includes roles at Royalty Pharma and Citi. Separately, Matt Skelton was promoted to Chief Commercial Officer as the company prepares for a potential commercial launch of atacicept. These moves reflect organizational steps taken ahead of anticipated clinical and commercial milestones.
Takeaway
The insider sale by Vera's CEO was executed under a previously established trading plan and coincides with a period of heightened market performance, refreshed analyst coverage, and internal staffing changes linked to commercialization planning. Investors tracking Vera will face near-term informational catalysts including the May 7 earnings date and ongoing clinical and competitive developments tied to atacicept.
Key points
- CEO Marshall Fordyce sold 22,951 shares on April 14, 2026, for $1,011,050 under a 10b5-1 plan adopted January 9, 2026.
- VERA stock has risen 10% over the past week and 105% over the past year; company market value is reported at $3.1 billion with earnings on May 7.
- Recent corporate moves include a board appointment and the promotion of a Chief Commercial Officer as the company prepares for a potential atacicept launch; several analysts have updated or reiterated ratings and price targets.
Risks and uncertainties
- Timing and results of upcoming catalysts such as the May 7 earnings report may influence stock performance and valuation - this impacts investors and equity markets tracking biotech names.
- Competitive clinical trial developments, referenced by analysts in relation to interim Phase 3 data from a competitor, introduce uncertainty around atacicept’s positioning in the IgA nephropathy market - this affects the biopharma and specialty pharma sectors.
- Reliance on a pre-arranged 10b5-1 plan means the disclosed sales followed an established schedule rather than ad hoc decision-making, which may affect interpretations of insider intent by market participants.